

FIRST TIME GENERIC APPROVAL

Brand Name	Taclonex®
Generic Name	calcipotriene and betamethasone dipropionate
Drug Manufacturer	Tolmar, Inc

New Drug Approval

Dosage form(s): 0.005%/0.064% Topical Suspension
Therapeutic equivalent code: AB
FDA Approval Date: May 11, 2020

Indications for Use

calcipotriene and betamethasone dipropionate topical suspension is indicated for:

- For the topical treatment of plaque psoriasis of the scalp in patients 12 years and older and plaque psoriasis of the scalp and body in patients 18 years and older

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.